Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective study.

backgroundLuminal-type breast cancer (BC) was characterized as hormonal receptor positive human epidermal receptor 2 negative (HR+/HER2-). The 70-gene signature (70-GS, MammaPrint) test is recommended for assessing recurrence risk and guiding adjuvant chemotherapy decisions for Luminal-type BC. This study updates previously established nomogram models to predict binary 70-GS risk for lymph node positive (LN+) and lymph node negative (LN-) luminal-type BC patients.

methodsThis retrospective study included 301 consecutive female patients with HR+/HER2- BC treated at Peking Union Medical College Hospital from November 2019 to December 2023. Patients' medical history, imaging reports, and clinicopathological features were reviewed. Forty risk parameters were compared between 70-GS high and low-risk patients among LN + and LN- groups. High risk stratification criterion in MonarchE and Natalee were compared between low and high 70-GS risk for the first time. Logistic regression was utilized to establish nomogram models predicting binary 70-GS risk for LN + and LN- patients. The models' prediction performance was evaluated utilizing accuracy, AUC of ROC curves, C-index, calibration curves, and decision curve analysis.

resultsSignificant differences were found between 70-GS high and low-risk patients in both LN + and LN- groups. Among LN + patients, parameters including childbirth number (p = 0.024), cardiovascular diseases (p = 0.037), US min. diameter of tumor (p = 0.034), Ki67 index (p < 0.001) and PR positivity (p = 0.007) were significant predictors. Among LN- patients, micro-calcifications (p = 0.011), PR positivity (p = 0.021), and Ki67 index (p < 0.001) were significant. The nomogram models showed high predictive accuracy, with AUC of 0.948 in the training set (C-index 0.948, 0.914-0.982, accuracy 0.907) and 0.923 in the testing set (C-index 0.923, 0.919-0.927, accuracy 0.828) for LN + patients and 0.917 in the training set (C-index 0917, 0.861-0.972, accuracy 0.870) and 0.917 in the testing sets (C-index 0917, 0.912-0.922, accuracy 0.808) among LN- patients. Calibration and decision curve analyses confirmed model reliability and clinical utility.

conclusionsThe updated nomogram models for predicting 70-GS risk in LN + and LN- luminal-type BC patients demonstrated improved prediction performance. The models facilitate individualized risk assessment and treatment decision-making, emphasizing tailored approaches based on lymph node status.